The Lewis lab has had a long interest in the mechanisms of various aspects of diabetic dyslipidemia, including postprandial lipemia, HDL lowering and hypertriglyceridemia, as well as the metabolic effects of free fatty acids on insulin action and secretion. Dr. Lewis and Adeli made the important observation that the intestine overproduces lipoproteins in insulin resistant states, elucidating a number of regulatory mechanisms of intestinal lipid mobilization and lipoprotein secretion. In his current funded work, Dr. Lewis is determining, in integrative physiological studies in humans and animal models, the mechanisms of intestinal lipid mobilization and lipoprotein secretion. In addition, he is the Principal Investigator of Diabetes Action Canada, one of the chronic disease networks funded through the Strategy for Patient-Oriented Research (SPOR) Initiative, and undertakes translational research with active patient engagement.
Practical definitions of severe versus familial hypercholesterolaemia and hypertriglyceridaemia for adult clinical practice.
Lancet Diabetes Endocrinol. 2019 Aug 21;:
Diabetes Obes Metab. 2019 Jul 31;:
Glucose and GLP-2 (Glucagon-Like Peptide-2) Mobilize Intestinal Triglyceride by Distinct Mechanisms.
Arterioscler Thromb Vasc Biol. 2019 Aug;39(8):1565-1573
Cell Mol Gastroenterol Hepatol. 2018 Nov 02;7(3):487-501
Cell Mol Gastroenterol Hepatol. 2018 Oct 12;7(2):313-337
Can J Diabetes. 2018 Sep 06;:
Diabetes Obes Metab. 2018 07;20(7):1751-1754
The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes.
Can J Cardiol. 2018 May;34(5):595-604
Trends Endocrinol Metab. 2018 Mar;29(3):151-163
Can J Diabetes. 2017 Dec;41(6):571-575
Senior Scientist, Toronto General Hospital Research Institute (TGHRI)
Professor, Department of Medicine; and Department of Physiology
Director, Banting & Best Diabetes Centre
Sun Life Financial Chair in Diabetes
Drucker Family Chair in Diabetes Research